OMS-527 is under clinical development by Omeros and currently in Phase I for Binge Eating Disorder. According to GlobalData, Phase I drugs for Binge Eating Disorder have a 95% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how OMS-527’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
OMS-527 is under development for the treatment of movement disorders such as Parkinson's disease, restless legs syndrome, compulsive disorders and for nicotine, cocaine, opioid and alcohol addiction as well as for binge eating disorder. The drug candidate targets phosphodiesterases 7 (PDE7).
Omeros is a biopharmaceutical company that discovers, develops and commercializes small-molecule and protein therapeutics for large-market and orphan indications. The company’s marketed product, Omidria is a phenylephrine and ketorolac injection for use during cataract surgery or replacement of intraocular lens (IOL). The company is investigating its product candidates for use in arthroscopic, ophthalmological, and other surgical procedures including thrombotic microangiopathies, mediated glomerulopathies, addictive and compulsive disorders among others. It is also evaluating preclinical product candidates for treatment of alternative pathway disorders, central nervous system disorders, metabolic, oncologic, musculoskeletal and other disorders. Omeros is headquartered in Seattle, Washington, the US.
For a complete picture of OMS-527’s drug-specific PTSR and LoA scores, buy the report here.